Articles related to BUSINESS & POLICY

GLP-1 agonists are increasingly recognized for their dual benefits in type 2 diabetes management and cardiovascular risk reduction, offering a multifaceted approach to patient care in an expanding global market.

The Inflation Reduction Act’s out-of-pocket cap on Medicare Part D spending marks a pivotal shift in healthcare economics, potentially altering prescription drug cost dynamics for millions of enrollees. Physicians should be aware of these changes to better support and inform their patients navigating these new financial landscapes.

In an era where specialty drug costs soar, Alternative Funding Programs present a complex solution, balancing cost containment with patient access to essential medications. These programs, while offering potential savings, may also introduce treatment delays and increased financial burdens for patients.

The acquisition of radiation oncology centers amid bankruptcy proceedings highlights the critical need for seamless transitions to uphold patient care standards.

Dr. Barbara L. McAneny’s withdrawal from the EOM program underscores the critical need for healthcare models to align with the realities of patient care, especially in community settings where the impact of social determinants is most pronounced.

Radiation oncology is facing a pivotal moment with a decline in residency applicants and unmatched positions, signaling a need for the field to reevaluate its approach to education, training, and diversity to ensure a sustainable future.